responses. This study investigated whether baseline and on-treatment differences in these responses predict response versus virological breakthrough during therapy with direct-acting antivirals (DAAs). Thirteen HCV genotype 1b-infected patients who had previously failed a course of pegylated IFN/ribavirin were retreated with asunaprevir/daclatasvir for 24 weeks. After pretreatment biopsy, patients were randomized to undergo a second biopsy at week 2 or 4 on therapy. Microarray and NanoString analyses were performed on paired liver biopsies and analyzed using linear mixed models. As biomarkers for peripheral IFN responses, peripheral blood natural killer cells were assessed for phosphorylated signal transducer and activator of transcription 1 (pSTAT1) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and degranulation. Nine of 13 (69%) patients achieved sustained virological response at 12 weeks off therapy (SVR12), and 4 experienced virological breakthroughs between weeks 4 and 12. Patients who achieved SVR12 displayed higher ISG expression levels in baseline liver biopsies and a higher frequency of pSTAT1 and TRAIL-expressing, degranulating natural killer cells in baseline blood samples than those who experienced virological breakthrough. Comparing gene expression levels from baseline and on-therapy biopsies, 408 genes (61.2-fold, P < 0.01) were differentially expressed. Genes down-regulated on treatment were predominantly ISGs. Down-regulation of ISGs was rapid and correlated with HCV RNA suppression. Conclusion: An enhanced IFN signature is observed at baseline in liver and blood of patients who achieve SVR12 compared to those who experience a virological breakthrough; the findings suggest that innate immunity may contribute to clearance of HCV during DAA therapy by preventing the emergence of resistanceassociated substitutions that lead to viral breakthrough during DAA therapy. (HEPATOLOGY 2018; C hronic hepatitis C virus (HCV) infection is characterized by a prominent type I and type III interferon (IFN) signature that is evident by increased expression of IFN-stimulated genes (ISGs) in the liver. Increased IFN signaling is also detectable in innate immune cells, such as natural killer (NK) cells, which represent the most frequent innate immune cells in the liver and express the IFN-a/b
C hronic hepatitis C virus (HCV) infection is characterized by a prominent type I and type III interferon (IFN) signature that is evident by increased expression of IFN-stimulated genes (ISGs) in the liver. Increased IFN signaling is also detectable in innate immune cells, such as natural killer (NK) cells, which represent the most frequent innate immune cells in the liver and express the IFN-a/b receptor. Because HCV persists at high titers in the presence of such immune responses, the contribution of innate immune activation to viral control is not clear.
Interestingly, high baseline ISG expression in the liver was associated with lower response to IFN-based therapy, (1) (2) (3) which was the standard of care for patients with chronic HCV infection for more than 20 years. Elevated levels of ISG expression among persons with chronic HCV infection are partly genetically determined by single-nucleotide polymorphisms (SNPs) rs12979860 and rs368234815 of the IFN lambda 3 and 4 genes, respectively, which are in strong linkage disequilibrium. (4, 5) Persons with the rs12979860[T] and rs368234815 [DG] alleles have higher ISG expression but poorer response to IFN-based therapy. (5, 6) The development of direct-acting antivirals (DAAs) has revolutionized the therapy of chronic HCV infection. (7) Combinations of DAAs can lead to eradication of chronic HCV infection in 90%-99% of individuals irrespective of host factors known to be negatively correlated with treatment response. (8, 9) However, some patients do fail DAA regimens. Resistance-associated substitutions, cirrhosis, high body mass index (BMI), and noncompliance have been associated with higher failure rates during DAA therapy. (10) Whether the endogenous intrahepatic IFN response plays a role in viral clearance during DAA therapy is not known. One study did report that ISGs were down-regulated with viral clearance during DAA therapy, but it did not assess the role of ISGs in the response to treatment. (11) Furthermore, how rapidly ISGs are downregulated in the liver and whether ISG levels at baseline or their decline during treatment are correlated with virological breakthrough or relapse remain unknown.
The aims of the current study were to investigate the early effects of viral suppression on ISG expression during therapy with an IFN-free, DAA-only regimen in subjects with chronic HCV infection who were prior partial or null responders to pegylated IFN (pegIFN)/ ribavirin (RBV) therapy and to determine whether baseline expression levels or early changes in ISG expression during therapy in the liver or response of IFN-sensitive innate immune cells in the blood were predictive of treatment outcome.
Materials and Methods

STUDY POPULATION
Clinical data and research samples from patients participating in a clinical trial to evaluate asunaprevir (ASV) 100 mg twice daily and daclatasvir (DCV) 60 mg once daily for 24 weeks (Bristol-Myers Squibb, Raritan, NJ) who were prior partial or null responders to pegIFN/RBV with or without cirrhosis (ClinicalTrials.gov, NCT01888900) were used in this analysis. A partial response was defined as a 2 log reduction by week 12 with detectable HCV RNA at week 24 during pegIFN/RBV therapy. A null response was defined as a 2 log reduction by week 12 of IFN therapy. In the current study, a responder was defined as a patient who achieved undetectable HCV RNA 12 weeks posttherapy (sustained virological response at week 12 off therapy [SVR12]). Virological breakthrough was defined as an increase in HCV RNA levels by 1 log from nadir while still on treatment.
STUDY DESIGN
Patients underwent an initial liver biopsy within 12 weeks before starting therapy with ASV/DCV. Patients were randomized to undergo a second liver biopsy at either week 2 or week 4 following the start of therapy. The primary endpoint of the trial was SVR12. Posttherapy, all patients were monitored every 4 weeks until week 12 and then returned for a final visit at 24 weeks off treatment. All patients provided written informed consent, and the protocol was approved by the institutional review board of the National Institute of Diabetes and Digestive and Kidney Diseases.
ARTICLE INFORMATION:
SERUM HCV RNA QUANTIFICATION
The serum HCV RNA level was quantitated using the Cobas TaqMan real-time polymerase chain reaction (Roche Molecular Diagnostics, Branchburg NJ), with a lower limit of detection of 10 IU/mL and a lower limit of quantification of 25 IU/mL.
LIVER BIOPSY RNA EXTRACTION AND MICROARRAY ANALYSIS
Core liver biopsies were immediately placed in RNAlater (Qiagen) and stored at -808C until handling. Total RNA extraction from liver tissue was performed on paired liver biopsies using the RNeasy kit (Qiagen). The quality of isolated total RNA was assessed using a bioanalyzer (Agilent Technologies, CA), and RNA integrity numbers were generally above 8.0 for all but three samples. Ten nanograms of total RNA from each sample was used for complementary DNA (cDNA) library preparation using the Ovation Pico WTA system V2 kit (NuGEN Technologies Inc., CA). The Ovation Pico WTA kit can successfully amplify samples with RNA integrity numbers as low as 2-5. For each array, 4 lg of cDNA was fragmented and biotin-labeled using the Encore Biotin module (NUGEN Technologies Inc.) and then added with hybridization control reagents (320 eukaryotic controls and control oligo B2; Affymetrix Inc., CA). Samples were hybridized with Affymetrix Human Gene 2.0 ST arrays and incubated at 458C for 18 hours, rotating at 60 rpm in a GeneChip Hybridization oven (Affymetrix Inc.). Hybridized arrays were washed and stained with the GeneChip HWS kit (Affymetrix Inc.) using Affymetrix 450 Fluidic Stations. Chips were scanned using the Affymetrix GeneChip scanner 3000. To access the efficiency of cDNA synthesis, Poly A controls (dap, lys, phe, thr; Affymetrix Inc.) were spiked into the samples, and hybridization controls (bioB, bioD, bioC, and Cre; Affymetrix Inc.) were added to monitor labeling efficiency, per the manufacturer's instructions. Samples were processed as batches of 32 chips at a time. Raw files from the Affymetrix Human Gene 2.0 array were preprocessed using RMA in R (Bioconductor oligo package, v.1.34.2) (Supporting Fig. S1 ). (12) Raw and processed data were deposited in Gene Expression Omnibus (GSE109278). Technical replicates were averaged for each sample, and averages were used for further analysis by linear mixed models using the Bioconductor limma package (v.3.26.8). (13) 
NANOSTRING nCOUNTER GENE EXPRESSION ASSAY
A customized probe set containing genes of interest from the 408 differentially expressed genes from the microarray data, in particular cluster 1 (Supporting Table S1 ), genes known to be associated with the innate immune response to HCV and the HCV life cycle based on a functional genomic screen (14) and a comprehensive literature review, (15) was designed and manufactured by NanoString and used for validation of microarray data. A code set specific to a 100-base region of the target mRNA was designed using a (3 0 biotin label) capture probe and a 5 0 reporter probe tagged with a specific fluorescent barcode, creating two sequencespecific probes for each target transcript. Probes were hybridized to 100 ng of total RNA for 19 hours at 658C and applied to the nCounter Preparation Station for automated removal of excess probe and immobilization of probe-transcript complexes on a streptavidin-coated cartridge. Data were collected using the nCounter Digital Analyzer by counting the individual barcodes. NanoString data were normalized using the nSolver Analysis Software (NanoString Technologies Inc.).
GENOTYPING
Genomic DNAs were used to identify the SNPs associated with rs12979860 and rs368234815 (previously designated as ss469415590) as reported. (4, 16) 
NK CELL ANALYSIS
Peripheral blood mononuclear cells (PBMCs) were separated from heparin-anticoagulated blood on Ficoll Histopaque (Mediatech, Manassas, VA) density gradients, washed 3 times with phosphate-buffered saline (Mediatech), and cryopreserved in 70% fetal bovine serum (FBS; Serum Source International, Charlotte, NC), 20% Roswell Park Memorial Institute 1640 (RPMI-1640; Mediatech), and 10% dimethyl sulfoxide (Sigma-Aldrich, St. Louis, MO). Thawed PBMCs were processed and stained as described below prior to analysis on an LSRII flow cytometer using FacsDiva Version 6.1.3 (BD Biosciences, San Jose, CA) and FlowJo Version 8.8.2 software (Tree Star, Ashland, OR).
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Staining
Thawed PBMCs (1 3 10 6 ) were stained with ethidium monoazide (EMA) for 10 minutes on ice, followed by staining with anti-cluster of differentiation 3 (CD3)-AlexaFluor700, anti-CD19-phycoerythrin (PE)-cyanine 5 (Cy5), anti-CD16-V500, anti-CD56-PE-Cy7, and anti-tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-PE (all from BD Biosciences) and with anti-CD14-PE-Cy5 (AbD, Raleigh, NC) for 25 minutes at 48C.
NK-Cell Degranulation
Thawed PBMCs were cultured overnight in RPMI-1640 with 10% FBS, 1% penicillin/streptomycin, 2 mM L-glutamine, and 10 mM 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid (Mediatech). The next day, PBMCs were counted and cultured in the presence of anti-CD107-PE (BD Biosciences) with or without target K562 cells (ATCC, Manassas, VA) as described (17) without addition of cytokines, then stained with EMA and lineage-specific antibodies as described above.
Phosphorylated Signal Transducer and Activator of Transcription 1 Staining
Thawed PBMCs (1.5 3 10 6 ) were rested in 0.5 mL RPMI-1640 with 10% FBS, 1% penicillin/streptomycin, and 2 mM L-glutamine (Mediatech) for 2 hours. Thereafter, cells were fixed with BD Cytofix buffer for 10 minutes at 378C and 5% CO 2 , centrifuged, permeabilized with BD Perm buffer III for 20 minutes on ice, washed twice, and resuspended in BD Phosflow Buffer (all from BD Biosciences). Cells were subsequently stained with anti-CD56-PE (Beckman Coulter, Brea, CA), anti-CD3-allophycocyanin, anti-CD20-peridininchlorophyll-protein/Cy5.5, and anti-phosphorylated signal transducer and activator of transcription 1 (pSTAT1)-Alexa488 (all from BD Biosciences) for 20 minutes at room temperature.
STATISTICAL ANALYSIS
D'Agostino and Pearson omnibus normality tests and Mann-Whitney tests were performed with GraphPad Prism 5.0a (GraphPad Software, La Jolla, CA). Two-sided P values <0.05 were considered significant.
Results
STUDY COHORT
Thirteen patients with HCV genotype 1b who were null responders (n 5 10) or partial responders (n 5 3) to a previous course of pegIFN/RBV therapy were enrolled into the study. The baseline clinical characteristics are shown in Table 1 . There were 6 women, mean age 59 years; 7 patients were Caucasian, 4 African American, and 2 Asian. Twelve of 13 patients had the rs12979860 CT or TT allele, and 12 of 13 patients had the rs368234815-DG genetic variant. Both variants are associated with an unfavorable response to IFN treatment. There was a 100% concordance between the two unfavorable SNPs. Mean serum Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; IL, interleukin.
alanine aminotransferase was 78 U/L, and mean HCV RNA level was 6.7 log 10 IU/mL. Five of 13 (38%) patients had cirrhosis confirmed by liver biopsy (Ishak fibrosis score 5-6), another 4 (31%) had advanced fibrosis (Ishak fibrosis score 3-4), and 4 (31%) had minimal or no liver fibrosis (Ishak fibrosis score 0-2).
VIROLOGICAL RESPONSE
Among the 13 subjects treated with ASV/DCV, 9 achieved SVR12 and 4 experienced virological breakthrough, which occurred between weeks 4 and 12 of therapy (Fig. 1A) . All patients regardless of eventual response to DAA therapy experienced an initial rapid decline in HCV RNA level within the first 72 hours of therapy (Fig. 1B) . There was no difference in mean HCV RNA levels at baseline and at week 2 (earliest time point of second liver biopsy) between treatment responders and those with virological breakthrough (Fig. 1C) .
CHANGES IN GLOBAL mRNA EXPRESSION DURING THERAPY
In vitro studies have reported that cellular factors play a pivotal role in the HCV life cycle. (18) (19) (20) (21) Therefore, we assessed changes in hepatic mRNA expression following DAA therapy by conducting a microarraybased transcriptome analysis using liver tissue from paired pretreatment and on-treatment (week 2 or 4) biopsies. Eleven patients with paired liver biopsies were studied in the microarray analysis (2 subjects with SVR12 who had not undergone the second biopsy at the time of RNA extraction and microarray analysis were excluded). Thus, among the 11 patients included in the transcriptome analysis, 7 achieved SVR12 and 4 experienced virological breakthrough, which occurred between treatment weeks 4 and 12. The expression data from the week 2 and 4 time points did not show any global segregation based on a similarity plot analysis (Supporting Fig. S2) . Thus, for subsequent data analysis, data from both week 2 and week 4 ontreatment biopsies were combined.
Comparing hepatic gene expression from biopsies obtained on treatment to baseline, 408 genes (61.2-fold, P < 0.01) were differentially expressed (Supporting Table S2 ). The majority of aberrantly expressed genes were down-regulated upon therapy. Most of the significantly down-regulated cellular pathways by the GO, Reactome, KEGG, and WikiPathways databases upon treatment were IFN signaling pathways, particularly those related to production of ISGs; and the top 25 down-regulated genes were predominantly ISGs (Tables 2 and 3; Supporting Tables S2 and S3) . Genes involved in mitochondrial and metabolic pathways (lipid and lipoprotein metabolism and oxidation) were enriched among those up-regulated upon DAA therapy (Supporting Table S4 ).
The heatmap of the transcriptomics data shows the expression levels of the 408 differentially expressed genes at the baseline and week 2/4 liver biopsies during DAA therapy (Fig. 2) . Among these 408 genes, there was a distinct cluster of genes on the baseline biopsy that separated patients who achieved SVR12 from those who experienced virological breakthrough, with the exception of a single patient (Fig. 2, cluster 1; Supporting Table S1 ). This led us to focus on the gene expression profiles at baseline between those who achieved SVR12 and those who had virological breakthrough. For this analysis, we selected genes of interest from Fig. 2 , cluster 1 (listed in Supporting Table S1), the most differentially expressed pathways, including IFN signaling pathways, IFN signaling, defense response to virus, regulation of viral genome replication, and metabolic pathways, from genes known to be associated with the innate immune response to HCV and the HCV life cycle based on a functional genomic screen (14) and detailed literature review. (15) Interestingly, patients who achieved SVR12 had higher pretreatment expression levels of ISGs in comparison to patients with virological breakthrough, with the exception of a single patient (Fig. 3) . ISGs with the greatest expression pretreatment included those with known antiviral function such as chemokine (C-C motif) ligand 20 (CCL20), 2 0 -5 0 -oligoadenylate synthetaselike protein, chemokine (C-X-C motif) ligand 10 (CXCL10), myxovirus (influenza) resistance 1, IFNinduced proteins with tetratricopeptide repeats 1, and DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 (DDX60). In addition, ISGs such as ISG15, ubiquitin-specific peptidase 18 (USP18), and suppressor of cytokine signaling 1 (SOCS1), which inhibit type I IFN but not type III IFN signaling, were higher in the pretreatment compared to the on-treatment biopsy (Supporting Table S5 ). To validate these findings, we determined the expression level of 46 genes by n-Counter-based NanoString analysis. The nCounter NanoString Gene Expression Assay is based on direct digital detection of genes of interest using targetspecific capture probe and color-coded reported probe pairs. The gene expression level is measured by tabulating the number of times the color-coded barcode for a gene is detected. The directionality and degree of fold changes obtained with NanoString were concordant with the microarray data (Supporting Table S6 ). Seven ISGs representing type I/III IFN signaling (CXCL11, CCL20), innate immunity (radical S-adenosyl methionine domain containing 2), cytokine signaling (ISG15), and defense response to virus (DDX60 and IFN regulatory factor 9 [IRF9]) pathways are shown in Fig. 4 . Baseline expression levels of five of seven selected ISGs were significantly higher by NanoString (all were significant by microarray) in those with SVR12 compared to those with virological breakthrough ( Fig. 4 ; Supporting Table S7 ). In addition, there was greater decline in intrahepatic expression levels of these seven ISGs between baseline and ontreatment (weeks 2 or 4) time points in patients with SVR12 compared to patients with virological breakthrough (Supporting Fig. S3 ).
BASELINE AND EARLY ON-TREATMENT NK CELL PHENOTYPE DIFFER BETWEEN PATIENTS WITH SVR12 AND THOSE WITH VIROLOGICAL BREAKTHROUGH
Next, we assessed whether the noted ISG induction was observed not only at the mRNA but also at the protein level. We had previously reported that the phenotype and function of NK cells were influenced by chronic exposure to low levels of endogenous IFNs in patients with chronic HCV infection. (22) This was evidenced by increased expression of pSTAT1, the phosphorylated state of a signaling molecule downstream of the IFN-a/b receptor, and increased levels of NK cell cytotoxicity in HCV-infected patients compared to healthy controls. (23) NK cells also expressed higher levels of TRAIL, an apoptosis-inducing effector molecule and itself an ISG. (22, 23) This phenotype normalized after DAA-induced HCV clearance. (24) As such, we asked whether the baseline NK cell phenotype and the phenotypes at early on-treatment time points differed between patients who achieved SVR12 to DAA therapy and those who failed the treatment. The gating strategy for NK cell analysis by flow cytometry is shown in Supporting Fig. S4 . Treatment responders displayed a higher frequency of pSTAT1 1 NK cells than patients who failed the treatment (P 5 0.03) (Fig. 5A) . This divergence was replicated by the observations of higher frequencies of TRAIL-expressing NK cells (P 5 0.03) for treatment Table S1 ), from the top differentially expressed pathways including IFN signaling pathways, IFN signaling, defense response to virus, regulation of viral genome replication, metabolic pathways, and genes known to be associated with the innate immune response to HCV and the HCV life cycle based on a functional genomic screen and from a detailed literature review. Patients who achieved SVR12 had higher pretreatment expression levels of ISGs in comparison to patients with virological breakthrough, with the exception of a single patient. responders (Fig. 5A ) and a trend toward greater cytotoxicity as supported by increased cell surface expression of the degranulation marker CD107a
1 NK cells (P 5 0.057). Because TRAIL (but not pSTAT1 and CD107a) is predominantly expressed in the CD56bright NK cell subpopulation, which constitutes <10% of the peripheral blood NK cell population, we also confirmed the differential TRAIL expression by CD56 bright NK cells (Fig. 5A, lower right panel) . Differential TRAIL expression was maintained at day 1 and week 2/4 on treatment (Fig. 5B,C) , whereas differential expression of pSTAT1 was lost on treatment (not shown). Collectively, these results indicate an increased IFN responsiveness at baseline in patients who subsequently mount an SVR12 compared to those who experience a breakthrough.
Discussion
HCV infection leads to activation of the innate immune response through sensing of extracellular and intracellular viral pathogen-associated molecular patterns by multiple pathogen recognition receptors. This process results in production of type I and/or type III IFNs and induction of various ISGs. This host defense response represents a strategy to contain the viral infection and restrict its spread to neighboring hepatocytes. However, in most cases, it is inadequate to eliminate acute HCV infection, and HCV persists in the presence of increased ISG levels in a substantial proportion of chronically infected patients.
(1) This high ISG expression has been associated with failure to respond to IFN-based treatment. (1, 25) In this study, we demonstrate that patients who responded to DAA therapy had higher baseline expression of ISGs compared to those who experienced a viral breakthrough with the exception of a single patient who failed therapy. This may have been due to the presence of many poor pretreatment predictors of response to DAA therapy in this patient including presence of cirrhosis, African American race, older age (70 years), high BMI (33) and the IFN lambda-3 genotype rs12979860 TT and IFN lambda-4 genotype rs368234815 DG/DG genotype, associated with poor response to IFN therapy. (6) This exception to the rule suggests that other host factors are important in predicting response to DAA therapy. Up-regulation of antiviral ISGs was associated with increased IFN signaling in NK cells at baseline with downstream expression of the ISG and effector molecule TRAIL and cytotoxic effector functions. Thus, our results suggest that the innate immune response may contribute to viral clearance with an IFN-free regimen. This interpretation is supported by the comparison of NK cells from the responder and virological breakthrough groups. The observation that NK cells from patients who responded to DAA treatment displayed higher expression of STAT1 and TRAIL prior to treatment and at day 1 and weeks 2 and 4 on treatment suggests a greater type I IFN response in patients who responded compared to those who experienced virological breakthrough.
The results are notable because prior studies have demonstrated that an up-regulated IFN response prior to treatment was associated with a high rate of treatment failure during IFN-based therapy. (1, 3, 26) The mechanism for this paradox is not completely understood. Recently, it was demonstrated that type III IFN, produced by hepatocytes, may be the primary driver of ISG production in the chronically HCVinfected liver. (27) The ISG profile of type III IFN is overlapping with but not identical to that of type I IFN. In particular, strong induction of SOCS1 and   FIG. 4 . Gene expression by NanoString at baseline based on response to DAA treatment. Shown are seven ISGs measured by NanoString representing different components of the innate immune response and demonstrating higher expression among patients who achieved SVR12 compared to those with virological breakthrough. Each dot represents an individual patient. Note that the Nanostring data from 1 patient with virological breakthrough are missing from this analysis due to technical problems with the assay, which probably explains the lack of significance for CXCL11 and IRF9 with the NanoString data (expression levels were significant using microarray data). Patients who responded to DAA therapy are shown in blue, and those who experienced virological breakthrough are shown in orange. Bars within boxes represent the median gene expression, and the upper and lower boundaries of the boxes represent the 75th and 25th percentiles of gene expression. USP18, which specifically inhibit the type I but not the type III IFN pathway, has been reported. (28) This is consistent with the finding that ISGs such as SOCS1 and USP18 were up-regulated in baseline liver biopsies of our patient cohort. On the other hand, NK cells do not express the type III IFN receptor chain 1, (29) suggesting that sufficient type I IFN is present to stimulate STAT1 phosphorylation and TRAIL expression in NK cells in our patient cohort.
Our study also demonstrates that ISG expression was rapidly down-regulated following initiation of DAA therapy even in patients who previously failed an IFN-based regimen and typically express elevated ISG levels. This is consistent with a previous report in which two HCV-infected chimpanzees were treated with a microRNA122 antagonist, with a rapid decline of hepatic ISG expression observed. (30) Downregulation of ISG expression during DAA therapy was also reported in a patient study. (11) However, that analysis used liver biopsies obtained prior to treatment and at the end of a 24-week course of treatment. Therefore, it was not possible to elucidate the effects of early viral suppression on ISG expression. In addition, the study included only patients who had never been treated, and RBV was included in the treatment regimen, which has been shown to improve IFN signaling. (25, 31) Collectively, our results extend the published data and suggest that viral replication is the inducer of high ISG expression. ISG expression data from the initial 72 hours, when there is the greatest decline in HCV RNA levels, would have provided stronger evidence. Unfortunately, we were unable to perform a third biopsy at this early treatment time point.
The study had several limitations. First, we only studied patients with HCV genotype 1b infection, and it is not known whether the conclusions can be extrapolated to other HCV genotypes, However, the capacities to induce ISGs of various HCV genotypes appear to be similar, (32, 33) and as such, we would expect the results from genotype 1b-infected patients from this study to be broadly applicable to all other genotypes. Second, among any given population of HCV-infected patients there are some who are easy to treat and some who are difficult to treat. We selected patients who failed previous pegIFNbased therapy (rs12979860 TT/TC alleles, rs368234815-DG allele, high baseline viral load, and advanced liver disease) as there is a pressing need to study this population. Whether the same findings apply to patients who are easy to treat is not yet clear.
In conclusion, we demonstrate that the baseline innate immune response contributes to a successful response to DAA therapy. We speculate that this innate immune response may prevent the emergence of resistance-associated substitutions that lead to viral breakthrough during DAA therapy.
